GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Goldman Sachs Group Inc. in a note issued to investors on Thursday.

GSK has been the topic of several other research reports. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 25th. Piper Jaffray Cos. assumed coverage on GlaxoSmithKline PLC in a research report on Friday, September 23rd. They set an “overweight” rating on the stock. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research report on Tuesday, September 27th. Finally, BNP Paribas lowered GlaxoSmithKline PLC from a “neutral” rating to an “underperform” rating in a research report on Tuesday, September 13th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $48.20.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC (NYSE:GSK) opened at 37.79 on Thursday. GlaxoSmithKline PLC has a 12 month low of $37.65 and a 12 month high of $45.58. The stock has a market cap of $91.94 billion, a price-to-earnings ratio of 248.62 and a beta of 0.93. The stock’s 50 day moving average price is $39.97 and its 200-day moving average price is $42.36.

The company also recently announced a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Friday, November 4th will be given a dividend of $0.459 per share. The ex-dividend date of this dividend is Wednesday, November 2nd. GlaxoSmithKline PLC’s payout ratio is 1,533.33%.

ILLEGAL ACTIVITY WARNING: This report was posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this report on another website, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at http://www.financial-market-news.com/goldman-sachs-group-inc-reiterates-buy-rating-for-glaxosmithkline-plc-gsk/1212541/.

In related news, major shareholder Plc Glaxosmithkline acquired 66,500 shares of GlaxoSmithKline PLC stock in a transaction dated Monday, October 24th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $931,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. FMR LLC increased its stake in shares of GlaxoSmithKline PLC by 29.8% in the second quarter. FMR LLC now owns 20,701,378 shares of the pharmaceutical company’s stock valued at $897,198,000 after buying an additional 4,757,238 shares in the last quarter. Thornburg Investment Management Inc. increased its stake in shares of GlaxoSmithKline PLC by 188.7% in the second quarter. Thornburg Investment Management Inc. now owns 1,025,410 shares of the pharmaceutical company’s stock valued at $44,441,000 after buying an additional 670,284 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of GlaxoSmithKline PLC by 24.7% in the second quarter. Ameriprise Financial Inc. now owns 3,038,134 shares of the pharmaceutical company’s stock valued at $132,800,000 after buying an additional 602,693 shares in the last quarter. Bailard Inc. bought a new stake in shares of GlaxoSmithKline PLC during the third quarter valued at about $10,671,000. Finally, Chartwell Investment Partners LLC increased its stake in shares of GlaxoSmithKline PLC by 519.1% in the second quarter. Chartwell Investment Partners LLC now owns 561,735 shares of the pharmaceutical company’s stock valued at $24,346,000 after buying an additional 471,005 shares in the last quarter. Institutional investors and hedge funds own 8.67% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.